MAP3K19 and idiopathic pulmonary fibrosis: In the present study, AXP1741 and another second-generation small-molecule inhibitor of MAP3K19, namely AXP2132, therapeutically modulated fibrosis in a humanized C.B-17SCID/bg mouse model initiated by the intravenous injection of stable IPF fibroblasts.